

**Sublingual immunotherapy in patients with house dust mite allergic rhinitis:
prospective study of clinical outcomes over a two-year period –
CORRIGENDUM**

J Y SOH, M THALAYASINGAM, S ONG, E X L LOO, L P SHEK, S S CHAO

doi:10.1017/S0022215116000025, first published online by Cambridge University Press, 19 January 2016

The above published paper included two errors. The details of the errors and corrections follow.

On page 2 under *Treatment*, the sentence:

The initiation and build-up phase of treatment followed the manufacturer's specifications; it comprised a gradual escalation of doses over an 11-day period, followed by maintenance treatment of 1200 index of reactivity daily, over a 24-month period.

should read:

The initiation and build-up phase of treatment followed the manufacturer's specifications; it comprised a gradual escalation of doses over an 11-day period, followed by maintenance treatment of **120** index of reactivity daily, over a 24-month period.

On page 5, the sentence:

The dosing regimen in this study was in accordance with the manufacturer's recommendations: the total cumulative dose was 6610 index of reactivity during the build-up phase, followed by 1200 index of reactivity daily.

should read:

The dosing regimen in this study was in accordance with the manufacturer's recommendations: the total cumulative dose was 6610 index of reactivity during the build-up phase, followed by **120** index of reactivity daily.

The authors apologise for any confusion caused by these errors.

Reference

Soh JY, Thalayasingam M, Ong S, Loo EXL, Shek LP and Chao SS. Sublingual immunotherapy in patients with house dust mite allergic rhinitis: prospective study of clinical outcomes over a two-year period. *The Journal of Laryngology & Otology* 2016;**130**:272–7.